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ABSTRACT
Background. Among hemodialysis patients, probing dry weight
is an effective strategy for improving control of hypertension.
Whether controlling hypertension improves or worsens symp-
toms among such patients remains unclear. The purpose of the
study was to develop a tool to evaluate symptoms and examine
the relationship of the change in these symptoms with blood
pressure (BP) control.
Methods. Among patients participating in the Hemodialysis
Patients Treated with Atenolol or Lisinopril (HDPAL) rando-
mized controlled trial, a conﬁrmatory factor analysis (CFA)
was performed to establish the relationship between symptoms
and organ systems. Next, the change in symptom scores per-
taining to organ systems was analyzed using a mixed model. Fi-
nally, the independent effect of lowering home BP on change in
symptoms was evaluated.
Results. Among 133 participants where symptoms were avail-
able at baseline, CFA revealed four level 1 domains: gastrointes-
tinal symptoms, dialysis-related symptoms, cardiovascular
symptoms and general symptoms. All except dialysis-related
symptoms were ascribed to uremia (level 2 domain). Uremic
symptoms improved over 6 months and then increased. Dialy-
sis-related symptoms (fatigue, cramps and orthostatic dizzi-
ness) did not worsen despite lowering home BP. Probing dry
weight was independently associated with an improvement in
cardiovascular symptoms such as shortness of breath.
Conclusions. Reducing BP through the use of a strategy that in-
cludes volume control and medication improves symptoms
seemingly unrelated to volume excess. In long-term hemodialy-
sis patients, treating hypertension using home BP measure-
ments may improve well-being.
Keywords: symptoms, blood pressure, cardiovascular, hemo-
dialysis, hypertension
INTRODUCTION
The management of hypertension among hemodialysis pa-
tients remains mired in controversy [1]. Two independent
meta-analyses of randomized trials among dialysis patients sug-
gest that blood pressure (BP) control among hemodialysis pa-
tients may be associated with reduced cardiovascular event rates
[2, 3]; however, large cohort studies suggest otherwise [4, 5].
The cohort studies show a strong and consistent association be-
tween both a lower baseline BP and time-dependent decline in
BP and subsequent all-cause mortality [6].
Probing dry weight through incremental reductions in
achieved postdialysis weight is an effective strategy in lowering
ambulatory BP among hemodialysis patients [7]. However,
critics point out that lowering dry weight can provoke intradia-
lytic hypotension and unpleasant symptoms and may even be
dangerous since it may provoke myocardial stunning due to
subclinical myocardial ischemia [8, 9]. Likewise, lowering BP
may cause orthostatic hypotension, fatigue and cramps andmay
make adherence to antihypertensive therapy problematic.
While we await randomized trials among hemodialysis pa-
tients of strategies to control BP with antihypertensive therapy
and probing dry weight, we can ask the question how the patients
feel and function while their dry weight is being probed and their
BP lowered. In this study, I hypothesize that symptoms in hemo-
dialysis patient will improve with lowering BP. BP, and not
weight, was chosen as a predictor of improvement in symptoms
because it is the ﬁnal outcome of effective lowering of dry weight.
MATERIALS AND METHODS
The Hypertension in Dialysis Patients Treated with Atenolol or
Lisinopril (HDPAL) was a randomized controlled trial that as-
signed hypertensive hemodialysis patients to either atenolol- or
lisinopril-based antihypertensive therapy and followed them
for 1 year for the primary endpoint of regression of left ven-
tricular hypertrophy [10]. Each group had a target home BP
of <140/90 mmHg, and the primary strategy used to lower BP
was to probe dry weight. The clinical trial was registered at
clinicaltrials.gov with registration number NCT00582114, and
primary results of this trial have been published [10]. The study
was approved by the Institutional Review Board of Indiana Uni-
versity and the Research and Development Committee of the
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Roudebush VA Medical Center, Indianapolis, and all subjects
gave written informed consent.
To accurately capture the adverse effects of atenolol and
lisinopril in the HDPAL trial, we used a structured question-
naire. This questionnaire was administered at baseline prior
to any administration of the drug and subsequently at monthly
intervals over the duration of the trial. The adverse effects
attributable to either atenolol or lisinopril included symptoms
such as nightmares; peripheral vasoconstriction, such as cold
hands and feet; upper respiratory infection, which is reported
more commonly among angiotensin-converting enzyme in-
hibitor users; dry cough and depression. Other symptoms were
more general in nature (e.g. gastrointestinal manifestations of
medication intake) or those related to excessive lowering of
BP, such as orthostatic hypotension or fatigue.
Each of the 20 questions was preceded by the following stem:
‘Over the last week, how frequently have you found yourself
bothered by the following symptoms?’ The symptoms were as
follows: fatigue or tiredness, chest pain, abdominal pain, cold
hands or feet, dizziness on standing, muscle cramps, diarrhea,
nausea, vomiting, dry cough, upper respiratory infection or com-
mon cold, shortness of breath, headaches, persistent dizziness,
numbness in hands or feet, decreased sex drive, decreased ability
to have sex, drowsiness or sleepiness, depression or feeling sad
and nightmares. The responses were constantly, frequently,
sometimes, rarely or never. Never was coded as 0, rarely as 1,
sometimes 2, frequently 3 and constantly as 4.
Based on this questionnaire, adverse effects that have been
typically attributed to atenolol or lisinopril were not found to
be different between drugs over time. For example, those rando-
mized to the lisinopril group did not have any increase in dry
cough or upper respiratory infections. In comparison, those as-
signed to atenolol did not have an increased frequency of night-
mares, cold hands and feet, drowsiness or depression. Because
the symptomswere collected in a structured way over the course
of the trial in this analysis, I asked the question whether the
symptoms deteriorated or improved. Also was there a relation-
ship between a change in symptoms and a change in home BP.
Home BP was recorded every month by the patients twice daily
(on waking up and before going to bed) in triplicate on each oc-
casion after the midweek dialysis for 4 days using a self-inﬂating
automatic oscillometric device (HEM-705 CP; Omron Health-
care). The strategy of dry weight reduction and antihypertensive
therapy escalation has been described elsewhere [10].
Statistical methods
Establishing symptom domains. Although symptoms can
be analyzed individually, conceptually symptoms are often
clustered to reﬂect disease in a particular organ or system. For
example, nausea, vomiting, diarrhea and abdominal pain can be
analyzed individually, but it may be better to treat them as a
cluster to reﬂect gastrointestinal disease. One approach would
be to simply average the scores of each one of the symptoms,
but more robust statistical techniques are now available. One
such technique is conﬁrmatory factor analysis (CFA). This
technique allows evaluation of whether an observed symptom
(e.g. nausea) is truly reﬂective of the latent variable (e.g. gastro-
intestinal domain). Unlike exploratory factor analysis, CFA
does not assume that error terms are independent and normally
distributed; therefore, it can ﬁt a model more adequately. By
providing a better ﬁt, it provides a better measure of the latent
variable by isolating noise. The reliability of the overall model
and model ﬁt can be calculated. Finally, modiﬁcation indices
allow for reﬁning the model ﬁt.
The CFA model developed used 133 participants with com-
plete data at baseline. I ﬁrst performed an exploratory factor
analysis and found three factors using maximal likelihood esti-
mation (MPlus 7.3.1; Muthen andMuthen, Statmodel, Los An-
geles, CA, USA). However, informed by clinical experience, I
divided the symptoms into domains that would reasonably be
considered reﬂective of the organ systems that they represent.
Dry cough, upper respiratory infection and nightmares were
not included in the analyses, as these questions were designed
more to evaluate the side effect proﬁle of the drugs.
The ﬁnal CFA model shows loading coefﬁcients for each
symptom to calculate the symptom score for each domain
both at baseline and at each subsequent month. Modiﬁcation
indices suggested including a covariance in the residual error
term for nausea and vomiting.
Evolution of symptoms over time. A mixed model was used
to assess the evolution of symptoms over time [11]. The outcome
variable was the symptom score. The independent variables were
the assigned drug with two levels of atenolol or lisinopril and the
visit as a continuous variable as well as an indicator variable (in a
separate model) with 12 levels starting from baseline. An inter-
action term (drug × visit) was included. The random component
of themodel included an intercept for subjects and coefﬁcient for
visit. A maximum likelihood estimation method was used for
modelﬁtting. The statistical signiﬁcance of the visit and visit × drug
interaction was tested next. Data presented are the marginal
means of the model and the standard errors.
After plotting the symptom domains over time, it became evi-
dent that the change in symptom scores was time dependent. Ac-
cordingly, a quadratic term for visit month was introduced and
visit month was modeled as a continuous variable. The remain-
ing part of the model is similar to that noted above.
Testing effect of lowering BP on symptom scores. To test
whether improvement in symptoms is mediated through lower-
ing of dry weight, a mixed effects model was again used. Given
that the change in symptoms was U-shaped and the maximal
change in symptoms occurred over the ﬁrst 7 months, I used in
the model noted above the baseline home systolic BP for each in-
dividual and change from baselinewithin individual in the mixed
model. In addition, I used the change frombaseline in postdialysis
weight as an independent variable. A sensitivity analysis where
the data from all 12 months were used with a quadratic term
for time and a further interaction term of change from baseline
within individual for home BP with time was performed.
To test the notion whether change in postdialysis weight in-
ﬂuences the dialysis symptom score, a mixed model was used.
The outcome variable was the dialysis symptom score, and the
following ﬁxed effects were used: time, time-squared, weight at
baseline, change in weight from baseline within individual and
an interaction term of the change in weight from baseline ×
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time. Random intercept for subject and random slopes for time
and change from baseline in weight was used. An unstructured
covariance was not required.
Conﬁrmatory factor analyses were performed using MPlus
7.3.1. Remaining statistical analyses were performed using
Stata 14.0 (StataCorp, College Station, TX, USA).
RESULTS
The overall results of the study have been previously published.
The mean age ± SD of this sample was 51.5 ± 12.4 years,
69% men, 81% blacks and 50% were randomized to atenolol.
The mean hemoglobin was 11.1 ± 1.3 g/dL, serum albumin
concentration 3.6 ± 0.5 g/dL, serum phosphorus concentration
6.1 ± 1.9 mg/dL and urea reduction ratio 74.4 ± 7.5%. The dis-
tribution of access was as follows: 58% ﬁstula, 14% graft and 28%
catheter. Baseline home BP was 165 ± 20/91 ± 12 mmHg with a
pulse rate of 78 ± 11 bpm. Baseline weight was 82.2 ± 19.1 kg.
Table 1 shows the distribution of symptoms in 133 partici-
pants. The top ﬁve symptoms were fatigue, drowsiness, numb-
ness in extremities, decreased sex drive and muscle cramps.
The least common symptoms were nightmares, common
cold, persistent dizziness, abdominal pain and chest pain.
Figure 1 shows the CFAmodel of two domains of symptoms:
dialysis-related symptoms and uremic symptoms. Uremic
symptoms included gastrointestinal, cardiovascular and general
symptoms. Thirteen symptoms encompassed these four do-
mains/subdomains. Although 20 symptoms were evaluated,
only 13 were retained in the ﬁnal model based on factor load-
ings, conceptual construct and model ﬁt. The model failed to
converge with the sexual dysfunction domain, therefore it was
removed. In the ﬁnal model ﬁt, each factor loading was >0.4,
indicating statistical validity to include the symptom in the do-
main. The reliability of the overall model was high (ρ = 0.87).
Figure 2 shows the evolution of symptoms over time among
participants randomized to one of the two drugs. To facilitate
comparison, all symptom scores were standardized to have a
mean of 0 and SD of 1. The top ﬁve graphs treat time (visit
month) as an indicator variable. The bottom ﬁve graphs treat
time as a continuous variable with a quadratic term included
for time. Except for cardiovascular symptoms that were greater
in the lisinopril group, there were no differences in symptom
scores in any domain between drugs at baseline. Over time,
there was improvement in cardiovascular, gastrointestinal and
general symptoms. There was no change in the dialysis symp-
tom score if time was treated as an indicator variable. However,
a signiﬁcant U-shaped relationship emerged when time was
treated as a continuous variable. There was no drug × time
interaction for any of the symptoms except for cardiovascular
symptoms, where a greater improvement was seen with lisino-
pril in the ﬁrst 6 months.
The trajectory of home BP and postdialysis weight and their
change from baseline are shown in the Supplementary data,
Appendix. Improvement in home BP was signiﬁcant (P <
0.0001) and was independent of the drug assignment. Improve-
ment in the postdialysis weight was signiﬁcantly more in the
lisinopril group (P < 0.0001).
Figure 3 shows the eight symptoms that demonstrated im-
provement over time. Symptoms were scaled from 0 to 100
and a higher score represents more symptoms. Symptoms
that improved included all gastrointestinal symptoms (nausea,
vomiting, diarrhea and abdominal pain) and a few other symp-
toms (depression, headaches, drowsiness and sex drive). No
time effect (indicating no signiﬁcant change in symptom over
time) or drug × time interaction effect (indicating no con-
founding effect of drug over time on symptoms) for any of
the 12 remaining symptom questions was noted.
Table 2 shows the mixed model derived symptom scores for
each of the domains. Since the relationship of symptoms over
time was U-shaped, to facilitate model interpretation the data
Table 1. Distribution of symptoms at baseline
Symptoms Never Rare Sometimes Frequently Constant Mean ± SD
Fatigue 21 (16%) 23 (17%) 52 (39%) 25 (19%) 12 (9%) 47 ± 29
Chest pain 68 (51%) 27 (20%) 25 (19%) 12 (9%) 1 (1%) 22 ± 26.5
Abdominal pain 68 (51%) 27 (20%) 27 (20%) 8 (6%) 3 (2%) 22 ± 26.8
Cold hands/feet 43 (32%) 23 (17%) 40 (30%) 14 (11%) 13 (10%) 37 ± 32.7
Orthostasis 52 (39%) 33 (25%) 38 (29%) 6 (5%) 4 (3%) 26.9 ± 26.6
Muscle cramps 30 (23%) 33 (25%) 49 (37%) 17 (13%) 4 (3%) 37.2 ± 26.8
Diarrhea 50 (38%) 28 (21%) 34 (26%) 17 (13%) 4 (3%) 30.6 ± 29.3
Nausea 45 (34%) 29 (22%) 35 (26%) 18 (14%) 6 (5%) 33.3 ± 30.1
Vomiting 65 (49%) 28 (21%) 29 (22%) 8 (6%) 3 (2%) 22.9 ± 26.8
Dry cough 57 (43%) 26 (20%) 35 (26%) 12 (9%) 2 (2%) 26.5 ± 27.4
Common cold 79 (59%) 28 (21%) 19 (14%) 5 (4%) 1 (1%) 16.1 ± 22.9
Short of breath 51 (38%) 32 (24%) 40 (30%) 8 (6%) 2 (2%) 27.1 ± 25.8
Headache 49 (37%) 31 (23%) 32 (24%) 17 (13%) 4 (3%) 30.5 ± 29.1
Dizzy all the time 80 (60%) 20 (15%) 23 (17%) 7 (5%) 3 (2%) 18.6 ± 26.6
Numbness in extremities 43 (32%) 19 (14%) 38 (29%) 20 (15%) 13 (10%) 38.9 ± 33.5
Decreased sex drive 50 (38%) 18 (14%) 24 (18%) 16 (12%) 19 (14%) 37.4 ± 37.1
Decreased ability to have sex 59 (44%) 12 (9%) 24 (18%) 15 (11%) 17 (13%) 34.1 ± 37.2
Drowsiness 31 (23%) 20 (15%) 46 (35%) 27 (20%) 9 (7%) 43 ± 30.5
Depression or feeling sad 53 (40%) 27 (20%) 35 (26%) 9 (7%) 9 (7%) 30.1 ± 30.7
Nightmares 87 (65%) 23 (17%) 13 (10%) 7 (5%) 3 (2%) 15.4 ± 25.3
Symptoms were coded as follows: never 0, rare 25, sometimes 50, frequently 75, constant 100.
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were truncated at 7 months because linearity was evident until
this point. However, a model that included all 12 months of
data with quadratic terms for time and appropriate interaction
terms for time-dependent BP change revealed similar results.
In each instance of uremic symptoms, there was a signiﬁcant dir-
ect relationship between the change from baseline in systolic BP
and improvement in symptom scores. For example, a 10 mmHg
reduction in home systolic BP reduced symptoms by 0.175 points
for cardiovascular symptoms. In the case of dialysis-related
symptoms, there was no signiﬁcant relationship between low-
ering of home systolic BP and worsening of symptoms. At least
the coefﬁcient was not negative, which would have indicated a
worsening of symptoms with lowering of home systolic BP. In
the case of cardiovascular symptoms, therewas a signiﬁcant and
direct relationship between lowering of postdialysis weight and
improvement in symptoms.
The independent effect of postdialysis weight on dialysis-
related symptoms is shown in Figure 4. There was a signiﬁcant ef-
fect on dialysis symptom score of time (−0.192 ± 0.06, P = 0.001)
and time-squared (0.015 ± 0.005, P = 0.003), but in addition there
was a signiﬁcant effect of the change from baseline in postdialysis
weight in dialysis symptom score (0.13/kg ± 0.05, P = 0.012) that
was mitigated over time [−0.93 ± 0.006 (P = 0.028)].
DISCUSSION
At baseline, symptoms could be classiﬁed as dialysis-related
symptoms and a hierarchical group of uremic symptoms
which were reﬂected by three level 1 domains: gastrointestinal
symptoms, cardiovascular symptoms and general symptoms.
The gastrointestinal symptoms were elicited by questions relat-
ing to nausea, vomiting, diarrhea and abdominal pain; cardio-
vascular symptoms by chest pain, shortness of breath and cold
extremities; general symptoms by evaluation of drowsiness,
headaches and depression; the dialysis-related symptoms were
elicited by three questions on fatigue, cramps and orthostatic
dizziness. The remaining questions could not be mapped to
F IGURE 1 : Hierarchical CFA of dialysis symptoms, ﬁnal model. Four level 1 latent variables represented in ovals were gastrointestinal symptoms
(gastrointestinal), cardiovascular symptoms (cardiovascular), dialysis symptoms (dialysis related) and general symptoms (general). One level 2
latent variable (uremia) is represented by three level 1 variables: gastrointestinal, cardiovascular and general. The arrows point to the observed
symptoms contained in rectangles within each domain. Numbers next to the straight arrows are the factor loadings. Each loading was both sig-
niﬁcant and >0.4. The arrows pointing to the squares are the residual variances and standard error of the residual variance. The curved arrows show
the covariances either among the error terms (vomiting and nausea) or covariances among the latent variables (dialysis-related and uremia). All
covariances were statistically signiﬁcant. Model ﬁt indices show that the χ2 was not signiﬁcant (P = 0.18), indicating that the structural equation
model identiﬁed the covariance matrix adequately. The root mean square error of approximation (RMSEA) was 0.035 and the standardized root
mean square residuals (SRMR) was 0.049. The comparative ﬁt index (CFI) was 0.978 and the reliability coefﬁcient of the model (ρ) was 0.86.
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any speciﬁc domains by CFA and therefore were excluded. The
CFA model had a good ﬁt as noted by the following observa-
tions: a non-signiﬁcant χ2-test for model ﬁt, P-value <0.05 for
RMSEA, CFI > 0.95, SRMR < 0.05 and a reliability coefﬁcient of
0.86. By usual metrics of CFA, these are considered adequate.
Given that the symptom burden in the hemodialysis patient
is high [12, 13], the study provides a framework by which symp-
toms could be evaluated and mitigated in the long term.
The most common symptom in this study was fatigue, the
mean score of which was 47, and 67% of the participants had
experienced fatigue at least some of the time. In fact, 28% felt
fatigue frequently or constantly. This is in line with what has
been reported by others [14–16]. Fatigue is directly related to
survival [17]. Furthermore, a single item question, ‘how long
does it take you to recover from a dialysis session?’ was related
to fatigue (r = 0.38, P < 0.0001) [15] and is directly related to
survival [18]. Even among patients with CKD not on dialysis,
fatigue is the most common symptom reported [19]. However,
no improvement in fatigue was noted in this study. Perhaps fac-
tors other than BP and volume, such as cytokine levels, aremore
important in causing fatigue [16, 20].
An improvement in most symptoms was seen in the study.
Of the gastrointestinal symptoms, all four symptoms improved.
Of the general symptoms, there was improvement in all three
symptoms, notably drowsiness, depression and headaches.
More importantly, there was no worsening seen in the dialysis
symptoms such as fatigue, orthostatic dizziness and muscle
cramps. In fact, a reduction in dry weight and lowering BP
may increase symptoms of fatigue, orthostatic hypotension
andmuscle cramps. However, if anything, there was a slight im-
provement, not deterioration, of the symptoms. Notably, the
improvement occurred at a time when dry weight was being
probed. This suggests that although in the short term probing
dry weight may lead to uncomfortable symptoms, in the long
term, lowering BP measured by using home BP monitoring
does not result in an increase in symptoms. Excess ﬂuid that
may accumulate in the liver tract may elicit gastrointestinal
symptoms. Therefore, it is biologically plausible that a reduc-
tion in BP (which we achieved predominantly by probing dry
weight) may improve such symptoms. Likewise depression,
drowsiness, headaches and sexual dysfunction, though not
being due to excess volume, may represent modiﬁable symp-
toms addressable by the simple expedient of probing dry weight
that is manifested by a lower BP.
Further evidence for the improvement of cardiovascular
symptoms due to probing dry weight comes from the
F IGURE 2 : Symptom score over time in the randomized trial. Scores are standardized to have a mean of 0 and SD of 1 to facilitate comparison
across groups. High scores represent more symptoms. The top ﬁve graphs show time as an indicator variable, whereas the bottom ﬁve treat time as a
continuous variable with a quadratic term added for time.Marginal modeledmeans are shownwith their standard errors. Signiﬁcant improvement
was seen with time in all but dialysis-related symptoms. Time effect reﬂects the P-value of time, while time × drug interaction is the P-value of the
interaction term.
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observation that a direct relationship existed between change
from baseline in postdialysis weight from 1 month to the next
and improvement in symptoms above and beyond BP. This
was not so for the gastrointestinal and general symptoms. In
other words, in a patient with cardiovascular symptoms,
both lowering dry weight and lowering BP can improve symp-
toms. We reported earlier that patients in the lisinopril group
remained more hypertensive and required greater lowering of
dry weight. It is possible that the early improvement in
symptoms in the lisinopril group may have been due to lower-
ing of dry weight.
It may be expected that probing dry weight may increase
dialysis-related symptoms. Figure 4 shows that the dialysis
symptom score improved early and worsened later when
there was no change in weight from baseline (this is expected
since the time and time-squared coefﬁcients were signiﬁcant).
However, with lowering of postdialysis weights therewas a greater
improvement in dialysis-related symptoms early, but also greater
F IGURE 3 : Graph of eight individual symptoms that showed improvement over time. Treatment × time interaction was not signiﬁcant, indi-
cating no unique effect of the drug. All gastrointestinal symptoms (top four graphs) and general symptoms (next three graphs) showed im-
provement, as did sex drive. The last symptomwas not included in the CFAmodel. Marginal modeledmeans are shown with their standard errors.
All symptoms are scaled from 0 to 100, where 100 represents most symptoms.
Table 2. Mixed model parameters for symptom scores
Parameter Symptom score
Cardiovascular Gastrointestinal General Uremia Dialysis related
Intercept 4.22*** ± 0.30 6.23*** ± 0.50 6.736*** ± 0.46 16.1*** ± 1.04 5.03*** ± 0.27
Month −0.122** ± 0.042 −0.301*** ± 0.06 −0.335*** ± 0.065 −0.726*** ± 0.136 −0.063** ± 0.039
BL home SBP (>140 mmHg) 0.008 ± 0.009 0.018 ± 0.016 0.025 ± 0.014 0.047 ± 0.033 0.003 ± 0.008
CFB home SBP (/10 mmHg) 0.175*** ± 0.051 0.209** ± 0.081 0.250*** ± 0.075 0.611*** ± 0.155 0.047 ± 0.048
CFB post wt (kg) 0.088* ± 0.044 0.05 ± 0.066 −0.004 ± 0.069 0.106 ± 0.137 0.045 ± 0.037
SD intercept 1.88 3.12 2.9 6.87 1.6
SD month 0.177 0.396 0.363 0.817 0.175
SD CFB post wt 0.153 0 0.254 0.344 0
σ 2.293 3.615 3.282 6.664 2.210
Given that the relationship of symptoms over time was U-shaped, to facilitate model interpretation the data shown are for the ﬁrst 7 months when the relationship was linear.
BL, baseline; CFB, change from baseline; SD, standard deviation derived from the random component of the model; SBP, systolic blood pressure; post wt, postdialysis weight.
*P < 0.05, **P < 0.01, ***P < 0.001.
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worsening later. Contrary to expectations, dry-weight reduction
early was associated with improvement in symptoms. One may
argue that after 10 months postdialysis weight may be increased
to mitigate symptoms. However, post-dialysis weight may meas-
ure different parameters before and after 6 months. Postdialysis
weight changes in the ﬁrst few months may reﬂect a change in
volume status. Mitigation of gastrointestinal symptoms may
cause weight gain. Thus, the change from baseline in weight
after the ﬁrst 6 months may reﬂect an accumulation of fat or
lean body mass. If this is true, then the U-shaped relationship
between symptoms and weight change can be explained based
on changes in body composition.
Some limitations must be pointed out. First, the question-
naire to assess symptoms was administered to only some of
the participants. This was because the idea of assessment of
symptoms was developed when the study was under way.
Second, not all participants completed the survey in each of
the 12months because the study was terminated early. Nonethe-
less, we had sufﬁcient responses to model changes in symptom
scores. We did not have a control group of placebo-treated pa-
tients. So it is difﬁcult to be certain whether a cause-and-effect
relationship exists. The improvement in symptoms waned in
the last 4–5 months of the trial. A placebo control would have de-
tected this effectmore clearly. As a cautionary remark, it is unlikely
that symptoms and BPwill be correlated outside an interventional
study. In otherwords, if we simplymeasured spontaneous changes
in BP and symptoms they are unlikely to be related. However, in
the context of an interventional study, where BP is controlled
through a deliberate reduction in dry weight and medication
use, improvement in symptoms is likely.
There are some strengths of this study. Incorporation of
patient-reported symptoms is novel and something that is dir-
ectly interpretable by the patients. Other novel features of this
study are the application of CFA to the study of symptoms in a
randomized trial and demonstration that lowering BP can ef-
fectively improve symptom scores.
This study demonstrates that it is possible to incorporate the
study of symptoms among a group of sick patients that should
take no more than 5 min to complete. Symptom evaluation
such as this may be particularly relevant to the dialysis patient.
Although the lifespan of dialysis patients may not necessarily be
prolonged without transplantation, lowering BP (predominantly
by probing dry weight) may keep them less symptomatic. It also
provides those caring for these patients with evidence to share
with their patients that lowering BP, in part through probing
dry weight, may improve well-being in the long term.
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